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INTRODUCTION: Malignancy is present in 10% of pheochromocytomas (PCC) and is deﬁned as
local/vascular inﬁltration of surrounding tissues or the presence of chromafﬁn cells deposits in distant
organs. The presence of isolated nodal recurrence is very rare and only 7 cases have been reported in the
medical literature.
PRESENTATION OF THE CASE: The case of a 32-y male with a symptomatic recurrence of a previously
operated (2-years ago) PCC is presented. Radiological and functional imaging studies conﬁrmed the
presence of multiple nodules in the surgical site. A radical left nephrectomy with extensive lymphatic
clearance in order to get an R0 resection was performed. The pathologist conﬁrmed the diagnosis of
massive locoregional nodal invasion.
DISCUSSION: A detailed histological report and a thorough genetic study must be considered in every
operated PCC in order to identify mutations and proﬁles of risk for malignancy. When recurrence or
metastastic disease is suspected, imaging and functional exams are done in order to obtain a proper
staging. Radical surgery for the metastatic disease is the only treatment that may provide prolonged
survival. If an R0 resection is not possible, then a debulking surgery is a good optionwhen the beneﬁt/risk
ratio is acceptable.
CONCLUSION: Isolated lymph nodal recurrence is very rare in malignant PCC, with only 7 cases previ-
ously published. The role of surgery is essential to get long-term survival because provides clinical and
functional control of the disease.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Pheochromocytoma (PCC) is a catecholamine-secreting neu-
roendocrine tumor originating from chromafﬁn cells derived from
the neural crest and arising from the adrenal medulla. Approx-
imately 10% of PCC are malignant, being malignancy deﬁned as
inﬁltration of surrounding organs or presence of chromafﬁn cells
deposits in locoregional lymphnodes (LN) and/or distant sites (spe-
cially liver, bones or lungs) [1].
We report the case of a patient with a malignant PCC (justi-
ﬁed as locoregional recurrence) who underwent an extended left
radical nephrectomy with regional lymphadenectomy to get a R0
resection. Diagnostic and therapeutic aspects of this unusual pre-
sentation are discussed.
2. Presentation of the case
An otherwise healthy 32-y male was admitted for headache
and palpitation as clinical expression of an hypertensive crisis. As
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background, a left laparoscopic adrenalectomy to treat a PCC was
performed two years before, requiring an open immediate reope-
ration for acute bleeding. The resected tumor was 5.5 cm diameter
and had neither necrosis nor vascular invasion, being its capsule
macroscopically reported as “preserved” and having a mitotic rate
of 1/10 high-power microscopic ﬁeld (HPMF) with presence of
some hyaline globules. The genetic panel screening showed no
mutations for RET proto-oncogene. Analytical exams showed an
elevated level of adrenalyn in 24h urine (150g, being normal
value <90g/24h).
Computed tomography (CT) scan described the presence of 6
nodules between 9 and 27mm extending along the left renal hilum
and downwards the para-aortic axis with compression of the left
renal vein, being highly suggestive of PCC recurrent disease (Image
1). Functional imaging with metaiodobenzylguanidine (MIBG) was
positive for pathologic deposits in left retroperitoneum (Image 2).
The patient underwent a left radical nephrectomy with
extended retroperitoneal and para-aortic dissection and an R0 sta-
tus was achieved (Image 3). Postoperative course was uneventful
and the patient discharged on postoperative day +10. Pathology
of the surgical specimen was reported as LN metastasis of PCC.
No adjuvant treatment was indicated. Three years after the opera-
tion, the patient remains asymptomaticwith normal analytical and
radiological/functional exams.
http://dx.doi.org/10.1016/j.ijscr.2015.06.011
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Image 1. CT scan. Three nodules can be seen in the para-aortic border and just
anterior and posteriorly to the left renal vein, which is compressed and narrowed.
3. Discussion
The last World Health Organization classiﬁcation of endocrine
tumors considers the concept of PCC exclusively for chromafﬁn
tumors arising from the adrenal medulla [1]. Genetic research has
identiﬁed up to 18 genes (both somatic and germ-line mutations)
involved in the pathogenesis of familial and sporadic forms of
PCC. Approximately 10–20% of PCC are associated with an speciﬁc
genetic syndrome (MEN-2, von Hippel-Lindau, Neuroﬁbromatosis
type I and familial PCC syndromes) but the risk of associated malig-
nancy in these cases is low. More recently, other causative genes
have been related to PCC, as the ones codifying the subunit B of the
succinate dehydrogenase B (SDHB), transmembrane protein 127
(TMP127) and MYC-associated factor X (MAX). Germline muta-
tions of the SDHB and MAX have been associated with a higher
rate of malignancy in cases of PCC (up to 90% and 25%, respec-
tively) [2]. Thus, genetic study of these mutations may be useful
in estimating the life-long risk for development of recurrent or
contralateraldiseaseandmalignantdifferentiation,havingan inﬂu-
ence in follow-up protocols [2,3].
Although there are no clearly deﬁned histologic characteristics
for malignancy, some features are considered suggestive: tumor
necrosis, mitotic rate greater than 3/30H.P.M.F., capsular and/or
vascular invasion, presence of large nests with central degen-
eration, lack of hyaline globules, high nuclear/cytoplasmic ratio,
monotony of cytological pattern and a spindle cell pattern [2,4].
Image 3. Reconstruction of the surgical ﬁeld with the surgical specimen of left
nephrectomy “en bloc” with the pathologic nodes (which can be seen opened in
central axis “like an orange”).
Nearly all of them are included in the PASS (Pheochromocytoma
of the Adrenal gland Scales Score) score, described by Thomson in
2002 and establishing that values <4, between 4 and 6 and >8 sug-
gest, respectively, low, intermediate and high risk of malignancy
PCC [5] (Fig. 1). Primary PCC larger than 5 cm have been associated
with a higher risk of malignancy and this is the main argument to
discuss the laparoscopic approach for big size PCC. Goffredo et al.
reported a series of 287 malignant PCC, being 72.5% larger than
5 cm. Although a regional lymphadenectomy was only performed
in 14% of the cases, an impressive rate of 67.8% metastatic involve-
mentwas found. Five years overall survivalwas signiﬁcantly higher
for patients with tumors measuring less than 5 cm (72.5% vs 27.5%)
and the authors waked up the debate about the need to perform
systematic staging lymphadenectomies in PCC larger than 5 cm [6].
Image 2. Nuclear scintigraphy with MIBG. An abnormal uptake can be observed in the left retroperiteum just in the anatomical area of the previously resected adrenal gland.
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Fig. 1. Parameters of the PASS Score as it was originally described by Thomson.
Tumor recurrence or persistence present, respectively, in the
6–23% and 3–13% of the PCC operated and is related to distant
site or LN metastasis, which may appear even 20 years after the
primary tumor [7]. Patients with liver or lung metastases tend to
have a worse prognosis than patients with isolated bone lesions.
Surgery is indicated as the best treatment when R0 resection or a
proper debulking operation can be obtained. Kim et al. reported 8
malignant PCC (out of a series of 119 in Korea) with one survivor
(the only patient undergoing surgery for LN and bone metastasis)
and the other 7 in this series (none of them had surgical treatment)
dying from progression of the disease [8]. In additon, Huang et al.
reported an overall disease-speciﬁc survival of 80% in a group of 5
patients having only LN metastases as distant disease when a R0
resection was performed, concluding that complete excision of the
metastatic disease is related to an excellent prognosis, with sur-
vival for more than 20 years being possible [9]. Rabii et al. reported
in 2001 the only case published of a laparoscopic approach for
resection of two para-aortic LN metastases (lower than 2 cm) of
a previously operated PCC [10]. In our case, we did not consider
performing laparoscopy because of the two previous operations,
compression of the vessels of the renal hilum and the need of
nephrectomy to achieve a R0 resection.
A mechanism of persistent or short term recurrent disease
because of non-oncological surgery of primary PCC has been
described by Rafat et al., who reported 5 cases in which the rupture
of the capsule or an incomplete tumoral resection leaded to local
recurrence in the retroperitoneum because of spillage of tumoral
cells. Even when radical or debulking surgery was performed, only
one patient was free of disease and 3 died of tumoral progression.
Radiological ﬁndings related to this mechanism are not easy to
differentiate preoperatively from regional LN metastases [11]. In
our case, the CT images showed some nodules located in the left
renal hilum and para-aortic margin and the report of the primary
PCC operated informed of an “entire capsule”. Then, we considered
the LN recurrence as the ﬁrst possibility although the diagnosis of
retroperitoneal “pheochromocytomatosis” was also in our mind.
Anyway we indicated surgery in order to obtain a R0 resection as
the only possibility of cure for the patient.
When complete resection of recurrent PCC can not be accom-
plished, surgical debulking and local therapies like ablation or
stereotaxic radiotherapy canprovide palliation. A lower tumor bur-
den leads to a decrease in catecholamine secretion and means less
risk of future cardio-vascular damage. Radiolabelled MIBG (I131) or
somatostatin analogues, separated or in synergistic combination,
may achieve control of the volume tumor and partial hormonal
response in 50% of the patients with metastatic PCC. Classical
chemotherapeuticdrugshavevery loweffectiveness andnowadays
efforts are in theway of investigating the role ofmolecular targeted
therapies (sunitinib/imatinib, everolimus or thalidomide).
4. Conclusion
Isolatedmetachronic LN involvement is a very rare presentation
of malignant PCC. Proper staging with radiological and functional
studiesmust be performed in order to evaluate the best therapeutic
option. Radical surgerymust alwaysbe consideredwhenaR0status
or a proper debulking can be achieved because it offers the best
chance for long term survival.
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